Targeting of XXXX with monoclonal antibody NCRC48--a possible approach for intravesical therapy.

@entity1 @entity150 @entity5 @entity2355
OBJECTIVE: To determine the localization of the anti- @entity2355 mucin monoclonal antibody (mAb) NCRC48 to @entity150 following intravesical administration. @entity1 AND METHODS: mAb NCRC48 (330-500 micrograms) radiolabelled with 111indium (11-17 MBq) was administered intravesically to 12 unselected @entity1 with radiological evidence of @entity150 . Tumour localization was assessed by gamma-camera imaging and by tissue biodistribution studies on biopsies obtained at cystoscopy at about 2 or 24 h after the procedure. After 24 h, whole blood radioactivity was measured and 3 weeks after the procedure the serum level of human anti-mouse antibodies was estimated using an ELISA method. RESULTS: Eleven @entity1 had @entity5 confirmed at cystoscopy (grades 1-3, stages pTa-pT2). The mean uptake of NCRC48 by @entity5 and by normal urothelium (expressed as the percentage of the instilled dose/g x 10(3) +/- SD) at 2 h was 3.42 +/- 3.68 and 0.41 +/- 0.77 (P < 0.05). After 24 h, the values for @entity5 and normal urothelium were 1.17 +/- 1.18 and 0.17 +/- 0.11, respectively. Areas of increased activity on the scintigrams were consistent with the position of the @entity5 at cystoscopy. No radioactivity was detected in blood at 24 h and there was no evidence of a human anti-mouse antibody response. CONCLUSION: The @entity2355 mucin may be a suitable antigen to study the potential of therapeutic strategies based on monoclonal antibody targeting of superficial @entity150 and may allow the development of more effective agents in the treatment of this condition.
